The pharmaceutical giant Pfizer, and Biogen forward a common Organisation: the Clinical Supply Chain Working Group (CSBWG). The joint working group is now starting a Proof-of-Concept project for the optimization of the pharmaceutical supply chain.By Alexandra cons
19. August 2019BTC$10,719 out,00 2.14%part Facebook Twitter LinkedIn xing mail
The Organisation of Pfizer and Biogen has quite prominent members. In addition to Pfizer and Biogen are among the big names of the group, GlaxoSmithKline, AstraZeneca, Merck and Deloitte. The Team operates from the open Workshop in the Pfizer Blockchain Center of Excellence.
the aim of the Clinical Supply Chain Working Group is the development of a Proof-of-Concept project. Through the Integration of the Blockchain technology, the digital inventory and tracking of the pharmaceutical clinical supply chain is possible. The participating firms need to capture the supply chains of the pharmaceutical agent is partially independent. The Blockchain can replace this work.Pfizer brings the Blockchain to the Tracking of drugs
the Ledger entry for the KitChain designated application developed using his or her Ledger entry-Selvedge-server. The Ledger domain-Selvedge-Server is based on Hyper Ledger Fabric. KitChain makes it possible for companies such as Pfizer, the shipments of packaged medications to keep track of. The Participants will be able to see what time a delivery will be sent and received. However, the persecution of logistics is likely to be only the first step of this larger-scale project.
For pharmaceutical companies such as Pfizer is the digital System is the gateway to the efficiency. Finally, the digital System offers more security and more control. The sender and the recipient who may have access to the Details of the shipments. Third parties have no access and can't modify the shipment details, therefore. A protected space for the participating companies.what's next for Pfizer-the consortium?
In an article by outsourcing Pharma, Senior Manager, Imran Shakur came to word:
We will find out what could be next steps, what other cases can we edit how the technical implementation looks like and how this could be applied in the different companies.
The next step for the project is a clinical study, in accordance with GxP regulations. According to Pfizer, the final goal could be an interoperable, transparent and auditable platform. Using this medicine could be tracked from the manufacturer to the patient. Chad Sklodosky, Director of the competence center for digital supply chains, Pfizer and Co-Chairman of the CSBWG, pointed to a promising future:
If we learn more about the technology, we can recognize the value for regulatory reporting. Hence, the process of the medicine responsibility of these locations and the tracking of upstream Investigational medicinal products can then be derived.
The Pfizer-consortium, however, is not the only attempt, the Blockchain technology in the pharmaceutical mainstream.
Attention: The crypto-compass is the first digital magazine for digital currencies and Blockchain Assets. He provides you with monthly exclusive assessments, Insights and comprehensive analysis of the current situation on the Blockchain- & crypto-markets. Only now and only for as long as the stock enough: In the Abo incl. FREE Bitcoin-T-Shirt